| Not Yet Recruiting | Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML NCT07374029 | David Avigan | Phase 1 |
| Not Yet Recruiting | A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies NCT06906380 | ARCE Therapeutics, Inc. | — |
| Not Yet Recruiting | Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML NCT07157514 | Actinium Pharmaceuticals | Phase 2 / Phase 3 |
| Not Yet Recruiting | An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and NCT06281847 | Advesya SAS | Phase 1 / Phase 2 |
| Recruiting | Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT04716452 | Keystone Nano, Inc | Phase 1 |
| Recruiting | Safety of MT-401-OTS in Patients With Relapsed AML or MDS NCT06552416 | Marker Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia NCT07011004 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS NCT06680752 | ARCE Therapeutics, Inc. | Phase 1 / Phase 2 |
| Withdrawn | CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) NCT05854966 | Wake Forest University Health Sciences | Phase 2 |
| Recruiting | Master Framework For Relapse or Refractory Acute Myeloid Leukemia NCT06459024 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | — |
| Recruiting | A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS NCT06372717 | Apollo Therapeutics Ltd | Phase 1 |
| Recruiting | Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen NCT06532084 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Terminated | CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leuk NCT06128044 | Caribou Biosciences, Inc. | Phase 1 |
| Recruiting | Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies NCT05949125 | AvenCell Europe GmbH | Phase 1 |
| Recruiting | Off-the-shelf CD123 CAR-NK for R/R AML NCT06201247 | Peking University People's Hospital | EARLY_Phase 1 |
| Recruiting | Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AM NCT06125652 | Xuzhou Medical University | Phase 1 / Phase 2 |
| Recruiting | A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia NCT06017258 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, V NCT05735184 | Kura Oncology, Inc. | Phase 1 |
| Recruiting | Venetoclax to Augment Epigenetic Modification and Chemotherapy NCT05317403 | Medical College of Wisconsin | Phase 1 |
| Unknown | Evaluation of the Safety and Efficacy of Esperanza Extract (PA001) NCT05587088 | Hospital Universitario San Ignacio | Phase 1 / Phase 2 |
| Recruiting | Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT05597306 | Terrence J Bradley, MD | Phase 1 |
| Recruiting | Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mu NCT05546580 | Oryzon Genomics S.A. | Phase 1 |
| Recruiting | A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) NCT05190471 | Bio-Path Holdings, Inc. | Phase 1 |
| Recruiting | Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Tran NCT05124288 | Ciceri Fabio | — |
| Recruiting | Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia NCT05506332 | University Hospital, Antwerp | Phase 1 |
| Recruiting | AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT05211570 | AB Science | Phase 1 / Phase 2 |
| Unknown | Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) NCT05488132 | Xuzhou Medical University | Phase 1 / Phase 2 |
| Unknown | Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Mye NCT04867928 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 2 |
| Recruiting | PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML NCT05105152 | Seattle Children's Hospital | Phase 1 |
| Active Not Recruiting | Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With NCT04898894 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia NCT04914845 | University of Colorado, Denver | Phase 1 |
| Terminated | CD123 Redirected T Cells for AML in Pediatric Subjects NCT04678336 | University of Pennsylvania | Phase 1 |
| Completed | Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome NCT04402541 | Cleave Therapeutics, Inc. | Phase 1 |
| Completed | Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/R NCT03957915 | Institut Paoli-Calmettes | EARLY_Phase 1 |
| Completed | Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment NCT04321161 | University of Freiburg | EARLY_Phase 1 |
| Active Not Recruiting | Lentivirally Redirected CD123 Autologous T Cells in AML NCT03766126 | University of Pennsylvania | Phase 1 |
| Terminated | A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML NCT03690154 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 |
| Unknown | A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for Fir NCT03053206 | All India Institute of Medical Sciences | Phase 2 |
| Completed | High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML NCT02768792 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Terminated | PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK) NCT02438761 | Institut Curie | Phase 2 |
| Terminated | Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia NCT02353143 | Menarini Group | Phase 1 |
| Completed | A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leuk NCT02204085 | Beth Israel Deaconess Medical Center | Phase 1 / Phase 2 |